6 results about "Ivabradine" patented technology

The invention provides a preparation method of a key intermediate of Hibomib. The key intermediate (compound V) of Hibomib is prepared by taking methyl 4-chlorobutyrate and 4 '-fluoro-2-hydroxyacetophenone as raw materials through a three-step reaction. The preparation method provided by the invention has the advantages of cheap and easily available raw materials, mild reaction conditions, simple and safe operation, good stereoselectivity, high yield and low cost, and is suitable for industrial mass production.

Some aspects provide novel ivabradine-like compounds and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the reduction of heart rate without a concomitant clinically significant fall in blood pressure with rapid termination of HR effect when stopping administration.

The invention discloses a sinoatrial node If channel inhibitor floating type gastric retention sustained-release tablet and a preparation method thereof, the floating type gastric retention sustained-release tablet is prepared from a sinoatrial node If channel inhibitor, a framework material, a floating aid, an expanding agent, a diluent, a lubricant and a film coating material, the sinoatrial node If channel inhibitor is ivabradine or a pharmaceutical salt thereof, and the framework material is a filler. The floating type gastric retention sustained release tablet is prepared through the steps of mixing, tabletting, film coating and the like. The floating type gastric retention sustained-release tablet for the sinus node If channel inhibitor can quickly float in a gastric environment, the gastric retention time is prolonged, so that the absorption time is prolonged, the bioavailability of active ingredients is improved, the preparation process is simple, and the technical effect of slow release can be realized.

Process for the synthesis of ivabradine of 141296 formula (I): and addition salts thereof with a pharmaceutically acceptable acid.

Provided herein are methods of treating or preventing an arrhythmia in a cardiac graft patient, wherein the method comprises administering combinations of anti-arrhythmic agents (e.g., amiodarone, metoprolol, ivabradine, and / or mexiletine) to the subject in need thereof.

The invention discloses a sinus node If channel inhibitor single-layer osmotic pump controlled release tablet and a preparation method thereof. The sinoatrial node If channel inhibitor single-layer osmotic pump controlled release tablet comprises a tablet core and a semi-permeable coating film wrapping the tablet core, and small drug release holes are formed in the semi-permeable coating film; the tablet core comprises a sinus node If channel inhibitor, a suspending aid, an adhesive, a filler and a lubricant; the sinus node If channel inhibitor is ivabradine or a pharmaceutical salt thereof. In order to solve the problem that the plasma concentration fluctuates violently due to the fact that the ivabradine hydrochloride tablet releases medicine too fast, the single-layer osmotic pump controlled release tablet is prepared, and compared with the ivabradine hydrochloride tablet, the single-layer osmotic pump controlled release tablet has the advantages that Tmax is obviously prolonged, the slow release effect is obvious, Cmax is reduced, the plasma concentration fluctuates little, and remarkable clinical benefits are achieved.